Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, reflecting both trading and price changes.

Connecticut-based Braidwell initiated a position of 2,188,320 Centessa shares in the fourth quarter. The quarter-end value of the position increased by $54.73 million, reflecting the new stake.

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Emerging Outlook: Biotech Summit Date: Thursday, February 12, 2026 Fireside Chat: 1:00 PM ET Event: TD Cowen 46th Annual Health Care Conference Date: Tuesday, March 3, 2026 Fireside Chat: 3:10 PM ET Event: Leerink Partners Global Healthcare Conference Date: Tuesday, March 10, 2026 Fireside Chat: 8:00 AM ET Event: Jefferies Biotech on the Beach Summit Date: Wednesday, March 11, 2026 Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients.

Tanager Wealth Management exited its entire CNTA position, reducing holdings by 598,044 shares in the fourth quarter. As a result, the quarter-end position value decreased by $14.50 million, reflecting both the share sale and stock price movement.

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder